Britain's medicines regulator said on Tuesday that any new or worsening reactions in patients' eyes arising from use of Sanofi's best-selling drug Dupixent should be promptly reviewed by healthcare professionals.
The UK's Medicines and Healthcare products Regulatory Agency said most ocular reactions seen with the drug are mild and can be managed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.